The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Hepatitis C
Interventions
DRUG

Daclatasvir plus Asunaprevir

Trial Locations (1)

Unknown

Myeong Jun Song, Daejeon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Soonchunhyang University Hospital

OTHER

collaborator

Dankook University

OTHER

collaborator

Chungnam National University Hospital

OTHER

collaborator

Konyang University Hospital

OTHER

collaborator

Eulji University Hospital

OTHER

collaborator

Saint Vincent's Hospital, Korea

OTHER

collaborator

Konkuk University Hospital

OTHER

collaborator

Cheongju St. Mary's Hospital, Cheongju, Korea

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

Eulji General Hospital

OTHER

lead

Myeong Jun Song

OTHER

NCT02580474 - The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure | Biotech Hunter | Biotech Hunter